InvestmentPitch Media Video Discusses LOVE Pharma’s Signing of Non-Binding LOI to Acquire 100% of Naltrexone Therapeutics Inc., a Pharmaceutical Technology Company with Significant IP Related to the Transdermal Delivery of FDA Approved Naltrexone
October 12, 2022 06:21 ET
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) has signed a non-binding Letter of Intent to acquire 100% of Naltrexone Therapeutics Inc., a...